A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Recruiting · NCT07717411 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-10 | NCT07717411 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoffmann-La Roche | 280 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Basil Clinical | Laurelton | United States | 4 |
| Irvine Center for Clinical Research | Irvine | United States | 4 |
| K2 Medical Research, LLC | Maitland | United States | 10 |
| Surrey and Borders NHS Foundation Trust | Chertsey | United Kingdom | 3 |
| Syrentis Clinical Research | Santa Ana | United States | 17 |
| Toronto Memory Program | Toronto | Canada | 9 |
| Xuanwu Hospital, Capital Medical University | Beijing | China | 38 |